Auro Pharma (Auro Pharma), a wholly owned subsidiary of Aurobindo Pharma at its meeting held today i.e. 01 January 2026 has approved the acquisition of non-oncology prescription formulations business of Khandelwal Laboratories on a going concern basis through a Business Transfer Agreement (BTA). Powered by Capital Market - Live News

Aurobindo Pharma announced that pending receipt of state government approval for setting up a captive solar power plant, the required investment for acquiring 26% in Swarnaakshu Solar Power will be completed on or before 31 March 2026, subject to the receipt of approval from the concerned state government. Powered by Capital Market - Live News

Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) inspected Unit-IV of APL Healthcare, a wholly owned subsidiary of the Company, situated at Palchur village and part of Palepalem Village Naidupeta Mandal, SPSR Nellore District, 524126, Andhra Pradesh, from 08 December to 17 December 2025.At the end of the current inspection, a �Form 483` was issued with 05 observations which are procedural in nature, and we will respond to the US FDA within the stipulated timelines. Powered by Capital Market - Live News

Aurobindo Pharma has received the Establishment Inspection Report (EIR) issued by the USFDA classifying Unit 1 of Apitoria Pharma, a wholly owned subsidiary of the company as `Voluntary Action Indicated (VAI)`. Powered by Capital Market - Live News

Net profit of Aurobindo Pharma rose 3.80% to Rs 848.45 crore in the quarter ended September 2025 as against Rs 817.38 crore during the previous quarter ended September 2024. Sales rose 7.73% to Rs 8236.96 crore in the quarter ended September 2025 as against Rs 7646.21 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales8236.967646.21 8 OPM %20.3720.48 - PBDT1705.111589.74 7 PBT1275.921207.46 6 NP848.45817.38 4 Powered by Capital Market - Live News